Menarini Group Unveils Groundbreaking Data at the 2026 ASCO Annual Meeting
Menarini Group Unveils Groundbreaking Data at the 2026 ASCO Annual Meeting
Florence, Italy and New York, May 25, 2026 – The Menarini Group, a prominent figure in the pharmaceutical world, is set to showcase pivotal new data at the highly anticipated American Society of Clinical Oncology (ASCO) Annual Meeting. With a commitment to advancing oncology treatments, the focus of their upcoming presentations will span seven compelling studies pertaining to both solid tumors and hematological malignancies.
The presentations will primarily highlight findings related to innovative therapies, particularly the elacestrant plus capivasertib regimen from the ELEVATE study. This regimen is being evaluated for its effectiveness in treating metastatic breast cancer (mBC) and will provide updates on elacestrant's potential role as a solo treatment option within adjuvant breast cancer care.
A notable highlight includes the presentation of a late-breaking segment by Karyopharm Therapeutics on selinexor’s performance within the phase 3 SENTRY trial focused on patients with myelofibrosis.
Insights from the ELEVATE Study
This phase 1/2 clinical trial is key to understanding the safety and early efficacy of elacestrant combined with capivasertib, particularly for patients with ER+/HER2- metastatic breast cancer exhibiting PI3K/AKT/PTEN alterations. The upcoming ASCO meeting will offer fresh insights into ongoing studies that are examining this combination treatment in different contexts:
- - ADELA Study: A phase 3 trial assessing elacestrant in conjunction with everolimus for ER+/HER2- mBC patients.
- - ELECTRA Study: Investigating the efficacy of elacestrant and abemaciclib for patients with brain metastases from ER+/HER2- breast cancer.
- - CAPELA Study: Focused on assessing capecitabine combined with elacestrant compared to capecitabine alone in advanced ER-positive breast cancer.
Ultimately, valuable data will be presented on the ELEGANT study, which explores the role of elacestrant as an adjuvant treatment for patients with node-positive early breast cancer who are at a heightened risk of recurrence.
Advancements in Hematological Malignancies
In addition to the groundbreaking data on breast cancer therapies, the ASCO meeting will spotlight new phase 2 tagraxofusp data for patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Naveen Pemmaraju, MD, from The University of Texas MD Anderson Cancer Center, will present this promising data during an oral session.
Moreover, Karyopharm Therapeutics will share crucial findings from the phase 3 SENTRY clinical trial concerning the usage of selinexor among JAK inhibitor-naïve patients with myelofibrosis. These presentations are expected to shed light on new avenues for treating these complex and challenging cancers.
A Commitment to Oncology Innovation
Elcin Barker Ergun, CEO of the Menarini Group, emphasized, "The extensive oncology data that will be presented, covering a range of solid tumors and blood malignancies, underscores our commitment to confronting the significant challenges posed by hard-to-treat cancers. Our unwavering focus is on driving innovation that translates into transformative therapies, providing significant benefits for patients and the healthcare professionals dedicated to their care."
Towards a Healthier Future
The Menarini Group, with a rich legacy in pharmaceuticals and diagnostics, continues to lay the groundwork for excellence in healthcare. Their latest findings presented at ASCO 2026 not only showcase their contributions to medical science but also amplify their long-standing dedication to addressing the unmet needs of cancer patients. With a robust pipeline and a focus on rigorous clinical trials, Menarini Group remains a pivotal player in advancing oncology therapeutics globally.
By participating in the ASCO Annual Meeting, Menarini aims to engage with the field's thought leaders, share critical insights, and foster collaborations that could pave the way for future innovations.
As they prepare to unveil these promising developments, the Menarini Group fortifies its role as a driving force in the fight against cancer, anchored in a comprehensive approach to delivering targeted therapies that matter.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.